Chinese Medical Journal

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab

Retrieved on: 
Wednesday, July 12, 2023
TKI, Malignancy, Renji Hospital, RCC, Clinical trial, Hope, Nephrectomy, Immunotherapy, PFS, Kidney, Shanghai Jiao Tong University School of Medicine, Global Research, Chinese, Death, Development, SSE, Chinese Medical Journal, HIV disease progression rates, Patient, Risk, National Medical Products Administration, IMDC, Carcinoma, Diagnosis, Axitinib, ORR, Safety, Disease, Pharmaceutical industry

Therefore, the need for new treatment options is more urgent for patients with medium and high-risk advanced RCC compared to low-risk patients.

Key Points: 
  • Therefore, the need for new treatment options is more urgent for patients with medium and high-risk advanced RCC compared to low-risk patients.
  • This supplemental new drug application is mainly based on the RENOTORCH study (NCT04394975).
  • The safety profile of toripalimab in the study was consistent with known risks, and no new safety signals were identified.
  • Dr. Jianjun ZOU, the Global Research and Development President of Junshi Biosciences, expressed her enthusiasm regarding the acceptance of this application.

The 6th Forum for World STM Journals: Focus on Jointly Building an Open and Innovative Community

Retrieved on: 
Sunday, June 25, 2023
Communications, Research, Media, Publishing, Science, Public Relations, Investor Relations, Dai, Tao, CAST, Benchmarking, Chinese Communist Party Committee Secretary, Media Group, CAE, University of Cambridge, Elsevier, Publicity Department of the Chinese Communist Party, Xi'an Jiaotong University, Diversification, John Wiley, Interview, SciEngines GmbH, Big data, British Non-Ferrous Metals Research Association, Policy, Anti-Party Group, Chinese Academy of Engineering, Exhibition, Advanced Photon Source, Ministry, Keynote, CAS, Speech, Chinese Academy of Sciences, Chinese Medical Journal, STM, AI, Pharmaceutical industry, Management, Medical device, Education

Themed "Jointly Building an Open and Innovative Community", the forum focused on STM journal development within the context of open science, inviting academic institutions, publishing organizations, and more from at home and abroad to discuss open science, publishing model transformations, big data and AI, and branding of STM journal.

Key Points: 
  • Themed "Jointly Building an Open and Innovative Community", the forum focused on STM journal development within the context of open science, inviting academic institutions, publishing organizations, and more from at home and abroad to discuss open science, publishing model transformations, big data and AI, and branding of STM journal.
  • He called for consensus-building in collaboration to advance open science development, creating a more open and innovative community.
  • His speech enunciated Shannxi's willingness to invest its rich cultural and scientific resources in more collaborations with the global community.
  • He complimented the forum for its focus on sustainability, equality, and inclusion while looking forward to a future where the community can have interactive dialogues.

Chinese Medical Journal Pulmonary and Critical Care Medicine Review Highlights Tumor Microenvironment-Targeted Cancer Immunotherapy

Retrieved on: 
Tuesday, June 20, 2023
Monoclonal antibody, Radiation, Survival, Cancer, Medical school, NSCLC, Antibody, Immunotherapy, Chinese Medical Journal, Patient, TME, Tumor microenvironment, Non-small-cell lung cancer, Critical Care Medicine (journal), Vaccine, Pharmaceutical industry

BEIJING, June 20, 2023 /PRNewswire/ -- Non-small cell lung cancer (NSCLC) is one of the most common and aggressive forms of cancer. Researchers have been exploring effective treatments to improve the survival rates of patients with NSCLC, such as by targeting the immune cells in the tumor microenvironment (TME). However, this approach is not successful in all patients. Now, a research team from China has conducted a detailed review to explore the role of TME in NSCLC and understand its predictive value in immunotherapy—a type of treatment that enables our immune cells to effectively destroy cancer cells.

Key Points: 
  • BEIJING, June 20, 2023 /PRNewswire/ -- Non-small cell lung cancer (NSCLC) is one of the most common and aggressive forms of cancer.
  • This review, led by Prof. Bo Zhu from the Third Military Medical University, China, was published online in the Chinese Medical Journal Pulmonary and Critical Care Medicine on February 25, 2023.
  • Previous studies indicate that TME plays an important role in the development of cancer and the responses of cancer cells to immunotherapy.
  • We anticipate that more targeted molecules will be chosen for the development of bispecific antibodies for cancer immunotherapy in the future," adds Prof. Zhu.

Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma

Retrieved on: 
Thursday, April 27, 2023
Malignancy, RCC, IDMC, OS, Nephrectomy, Immunotherapy, PFS, Trial of the century, Kidney, Chinese, Death, Development, SSE, HKEX, Chinese Medical Journal, HIV disease progression rates, Patient, Risk, IMDC, Carcinoma, Diagnosis, R, Axitinib, ORR, Safety, Disease, Renal cell carcinoma, Pharmaceutical industry

RENOTORCH is a multi-center, randomized, open-label, active-controlled phase 3 clinical study evaluating toripalimab in combination with axitinib for the first-line treatment of patients with intermediate to high risk, unresectable or distant metastatic renal cell carcinoma (“RCC”).

Key Points: 
  • RENOTORCH is a multi-center, randomized, open-label, active-controlled phase 3 clinical study evaluating toripalimab in combination with axitinib for the first-line treatment of patients with intermediate to high risk, unresectable or distant metastatic renal cell carcinoma (“RCC”).
  • The Independent Data Monitoring Committee (IDMC) has determined that the primary endpoint of progression free survival (“PFS”, based on independent radiographic review) has met the pre-defined efficacy boundary.
  • Junshi Biosciences will communicate with regulatory authorities regarding matters related to the supplemental new drug application in the near future.
  • Globally, renal carcinoma is the third most common type of malignancy in the urinary system, and RCC accounts for 80%-90% of all cases.

Chinese Medical Journal Reviews Bacterial Affinity for Iron and its Clinical Implications

Retrieved on: 
Thursday, January 12, 2023
Peking University Third Hospital, Infection, Siderophore, Absorption, Gram-negative bacteria, Human body, Health, Bacteria, Iron, Genetically modified bacteria, Pseudomonas fluorescens, Survival, Therapy, Chinese Medical Journal, Raman, Human, Vaccine

Infecting bacteria must compete with humans for iron, and so have evolved various mechanisms for iron uptake.

Key Points: 
  • Infecting bacteria must compete with humans for iron, and so have evolved various mechanisms for iron uptake.
  • A group of Chinese researchers have recently reviewed these mechanisms and outlined clinical strategies for safeguarding human health from bacterial infections.
  • Their paper was published in Volume 136, Issue 16 of the Chinese Medical Journal on 20 August 2022.
  • So, to counter bacterial invasions and the subsequent bacterial uptake of iron, the human body has developed smart defense mechanisms.

Chinese Medical Journal Article Reveals Gender-Based Differences in Lung Cancer Risk Among Non-Smokers

Retrieved on: 
Thursday, January 12, 2023
Peking Union Medical College, Disease, Non-Smokers' Rights Association, Smoker, National Cancer Center, Chinese, University of the Chinese Academy of Sciences, Lung cancer, Biomarker, Risk, Medicine, Air pollution, Chinese Academy of Medical Sciences COVID-19 vaccine, Squamous cell carcinoma, Woman, City, Chinese Medical Journal, NLCS, Adenocarcinoma, Research, Male, Incidence, Female

So, a team of researchers from China published a multicenter, population-based cancer screening study under the China National Lung Cancer Screening (NLCS) Program, in the Chinese Medical Journal on June 5, 2022.

Key Points: 
  • So, a team of researchers from China published a multicenter, population-based cancer screening study under the China National Lung Cancer Screening (NLCS) Program, in the Chinese Medical Journal on June 5, 2022.
  • After an average follow-up period of 4.8 years, 3,351 participants from the cohort were diagnosed with lung cancer.
  • Interestingly, they observed that males displayed a higher risk of developing lung cancer than their female counterparts.
  • Title of original paper: Sex disparity of lung cancer risk in non-smokers: a multicenter population-based prospective study based on China National Lung Cancer Screening Program

Chinese Medical Journal Study Finds New Genetic Variant Linked to Pancreatic Cancer Prognosis

Retrieved on: 
Monday, January 9, 2023
Research, DNA, Single-nucleotide polymorphism, Pancreatic cancer, Malignancy, Patient, Prognosis, Chinese Medical Journal, Quantitative trait locus, SNP, Meta-analysis, Survival, Gene, Pharmaceutical industry, Vaccine

BEIJING, Jan. 9, 2023 /PRNewswire/ -- Pancreatic adenocarcinoma (PAAD) is a malignancy with an extremely poor prognosis and high fatality rate. Despite advances in medical technologies over the past decades, early detection and effective treatments are limited. Genetic factors considerably influence the overall survival of patients with PAAD. Naturally, several studies have attempted to discover genes associated with PAAD prognosis or overall survival. However, the findings were not consistent owing to limited sample sizes and the heterogeneity in studies' design.

Key Points: 
  • BEIJING, Jan. 9, 2023 /PRNewswire/ -- Pancreatic adenocarcinoma (PAAD) is a malignancy with an extremely poor prognosis and high fatality rate.
  • Naturally, several studies have attempted to discover genes associated with PAAD prognosis or overall survival.
  • Their paper, published in Volume 135, Issue 11 of the Chinese Medical Journal, was made available online on July 13, 2022.
  • Prof. Xiaoping Miao, senior author on the study, comments, "The regulatory genetic variants that affect PAAD prognosis are largely unknown.

Chinese Medical Journal Review Offers Valuable Insights into Severe Asthma

Retrieved on: 
Wednesday, December 14, 2022
Respiratory Medicine, Cytokine, Azithromycin, Bronchial thermoplasty, Risk, Imperial College London, Diagnosis, ICS, Chinese, Bronchial hyperresponsiveness, Biomarker, Asthma, IL-5, Chinese Medical Journal, Antibody, Immunoglobulin E, Interleukin, Epigenetics of diabetes Type 2, Phenotype, Pharmaceutical industry

This paper was made available online on May 28, 2022, and was published in Volume 135, Issue 10, of the Chinese Medical Journal .

Key Points: 
  • This paper was made available online on May 28, 2022, and was published in Volume 135, Issue 10, of the Chinese Medical Journal .
  • However, oral corticosteroid therapy for severe asthma could be minimized by introducing antibody therapies, which are targeted for those with Type 2 inflammation.
  • Prof. Chung concludes, "Antibody treatments targeted at the Type-2 targets, such as anti-IL5, anti-IL5Ra, and anti-IL4Ra antibodies, are now available for treating severe eosinophilic asthma, in addition to anti-immunoglobulin E antibody for severe allergic asthma.
  • In summary, molecular phenotyping of the airway inflammatory process is already paving the way towards the precision treatment of severe asthma and will go on expanding.

Chinese Medical Journal Study Highlights Risks of Subpar Muscle Characteristics

Retrieved on: 
Wednesday, December 7, 2022
Degenerative disease, Arm, Ageing, Peking University, Public health, Cancer, Area studies, Death, Muscle, Chinese Medical Journal, Mortality, Associate, Risk, Dietary supplement, Sarcopenia

This question has been the focus of various cohort studies, which explored the relationship between all-cause mortality and muscle mass-related measures, muscle strength, and muscle quality.

Key Points: 
  • This question has been the focus of various cohort studies, which explored the relationship between all-cause mortality and muscle mass-related measures, muscle strength, and muscle quality.
  • The researchers measured muscle mass and grip strength using calibrated instruments, and calculated arm muscle quality as the ratio of grip strength to arm muscle mass.
  • Another interesting finding was that, among Chinese adults, muscle mass in the arms or trunk seems to be better at predicting all-cause mortality than muscle mass in the legs.
  • Title of original paper: Associations of muscle mass, strength, and quality with all-causemortality in China: a population-based cohort study

Hematopoietic Stem Cell Transplantation in China: Highlights from a Chinese Medical Journal Review

Retrieved on: 
Thursday, November 3, 2022
Chinese Medical Journal, Survival, Chinese, Mental health, Hague Hijacking Convention, Technology, Infection, Hematological Cancer Research Investment and Education Act, Patient, Hematopoietic stem cell transplantation, HLA, Review, B cell, HSCT, Adoption, Medical device, Pharmaceutical industry

BEIJING, Nov. 3, 2022 /PRNewswire/ -- Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a revolutionary therapy and currently the only curative option for hematological cancers and some immune or metabolic disorders.

Key Points: 
  • Since the first successful allo-HSCT in China in 1981, the country has made tremendous contributions to this therapeutic field.
  • In a recent paper published in the Chinese Medical Journal , clinicians summarized the current status and trends of allo-HSCT in China and discussed the future of this field.
  • Their paper was made available online on July 22, 2022, and was published in Volume 135 Issue 12 of the journal.
  • The Beijing Protocol provided a framework for "haploid HSCT (haplo-HSCT)" technology, which uses stem cells obtained from half-matched donors.